Regorafenib

Regorafenib Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

In September 2012, theUSFDAapproved regorafenib for the treatment of patients with metastatic colorectal cancer (CRC), especially those for whom standard therapies have failed, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, ananti-EGFRtherapy. Regorafenib is a multikinase inhibitor with potent inhibitory activity versus VEGFRs and PDFRs. Both of these classes of receptors are expressed on tumor cells and affect proliferation and angiogenesis. Regorafenib inhibited growth in murine xenograft models for colon, breast, renal, lung, melanoma, pancreatic, and ovarian tumors when dosed at 10–30 mg/kg. Regorafenib is a fluorinated analog of sorafenib, a multikinase inhibitor co-marketed by Bayer and Onyx for the treatment of kidney and liver cancer. The synthesis of regorafenib is accomplished in two steps from commercially available starting materials. 4-Aminophenol is coupled to 4-chloro-N-methyl- 2-pyridinecarboxamide to give 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline. Subsequent treatment with 4-chloro-3-(trifluoromethyl)phenyl isocycanate affords the urea, regorafenib.

Charakteristisch

Class: receptor tyrosine kinase
Treatment: colorectal cancer, GIST, HCC
Elimination half-life = 26-28 h
Protein binding = 99.5%

Verwenden

BAY 73-4506 (Regorafenib) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf.

Definition

ChEBI: A pyridinecarboxamide obtained by condensation of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]pyridine-2-carboxylic acid with methylamine. Used for for the treatment of metastatic colorectal cancer in patients who have previ usly received chemotherapy, anti-EGFR or anti-VEGF therapy.

Regorafenib Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Regorafenib Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
Yangzhou Qinyuan Pharmatech Co.,ltd	+86-18752526868	jennysun@yzqyyykj.com	China	64	58
Hebei Yanxi Chemical Co., Ltd.	+8617531190177	peter@yan-xi.com	China	6011	58
XuZhou Magic Biotechnology Co., Ltd.	+undefined13921770081	SVP01@magicbiotech.cn	China	92	58
Henan Fengda Chemical Co., Ltd	+86-371-86557731 +86-13613820652	info@fdachem.com	China	18222	58
Capot Chemical Co.,Ltd.	571-85586718 +8613336195806	sales@capotchem.com	China	29797	60
Beijing Cooperate Pharmaceutical Co.,Ltd	010-60279497	sales01@cooperate-pharm.com	CHINA	1811	55
Henan Tianfu Chemical Co.,Ltd.	+86-0371-55170693 +86-19937530512	info@tianfuchem.com	China	21689	55
Hangzhou FandaChem Co.,Ltd.	008657128800458; +8615858145714	fandachem@gmail.com	China	9341	55
Nanjing Finetech Chemical Co., Ltd.	025-85710122 17714198479	sales@fine-chemtech.com	CHINA	885	55
ATK CHEMICAL COMPANY LIMITED	+undefined-21-51877795	ivan@atkchemical.com	China	32686	60

755037-03-7()Verwandte Suche:

---

• 4-[4-({[4-chioro-3-(trifluoroMethyl)phenyl]carbaMoyl}aMino)-3-fluorophenoxy]-pyridine-2-carboxylic acid MethylaMide
• REGORAFENIB BAY 73-4506 BAYER HEALTHCARE (SEE ALSO COLORECTAL, LUNG, STOMACH) PHASE II(REGORAFENIB) PHARMACEUTICALS (888) 842-2937WAYNE, NJ
• 4-[4-[[[[4-Chloro-3-(trifluoroMethyl)phenyl]aMino]carbonyl]aMino]-3-fluorophenoxy]-N-Methyl-2-pyridinecarboxaMide
• 4-[4-[N'-(4-Chloro-3-trifluoroMethylphenyl)ureido]-3- fluorophenoxy]pyridine-2-carboxylic Acid MethylaMide
• regorafinib
• Regafenib
• Reggae sorafenib
• Regorafenib C3X-1410
• Regorafenib, >=98%
• 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea
• Fluoro-Sorafenib
• 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide Regorafenib BAY 73-4506
• Stivarga(regorafenib)
• 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide
• Regorafenib
• BAY 73-4506
• BAY 73-4506(Regorafenib)
• 4-(4-(3-(4-chloro-3-(trifluoroMethyl)phenyl)ureido)-3-fluorophenoxy)-N-MethylpicolinaMide
• 842-2937WAYNE
• China Hot sale Regorafenib with best price and high quality CAS NO.755037-03-7
• CS-1930
• Regorafenib - BAY 73-4506 | Stivarga
• CS-169
• Regorafenib (BAY73-4506,Fluoro-Sorafenib)
• REGORAFENIB; BAY 73-4506; SORAFENIB; BAY-73-4506; BAY 73 4506
• Regorafenib(W.S)
• Re orafenib
• 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-
• 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-3-carboxamide
• 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-...
• 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide
• α-D-Glucopyranuronicacid,methylester,2,3,5-triacetate
• Stannane,tetrakis(5-methylethoxy)-
• Regorafenib (BAY 73-4506)
• RG-API
• 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-met
• Regorafenib,HUVECs,Autophagy,Vascular endothelial growth factor receptor,Colo-205,FGFR,SCFR,RET,NIH-3T3,antiangiogenic,Antitumorigenic,PDGFR,inhibit,c-Kit,HAoSMCs,Platelet-derived growth factor receptor,tumor,Inhibitor,Hep3B cell,CD117,Raf kinases,Fibroblast growth factor receptor,VEGFR,Raf,786-O
• 755037-03-7
• 755037-07-3
• 755-37-03-7
• 755037-03-8
• C21H15ClF4N4O3
• Inhibitors
• Anti-cancer&immunity
• Amines
• Aromatics
• Heterocycles
• Intermediates & Fine Chemicals
• Pharmaceuticals
• API
• API
• 755037-03-7